Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221230 · ClinicalTrials.gov registry record · Phase 2
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo
A Phase 2 study, sponsored by Neumora Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT04221230 is a Phase 2 study that has completed, run by Neumora Therapeutics. The registered enrollment target is 204 participants.
The verdict
NCT04221230, a Phase 2 study, has completed, sponsored by Neumora Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
Interventions
- DRUG Placebo
- DRUG NMRA-335140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2020-01-03 |
| Est. Completion | 2022-06-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04221230
The ClinicalTrials.gov registry entry for NCT04221230 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neumora Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04221230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04221230 about?
NCT04221230 is a clinical study titled "Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs Placebo". A proof of concept (POC) study evaluating the impact of NMRA-335140 (BTRX-335140) relative to placebo on symptoms of major depressive disorder (MDD) in adult participants with MDD and symptoms of anhedonia and anxiety following 8 weeks of double-blind treatment as assessed by the HAMD-17 Scale.
What is the current status of trial NCT04221230?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2020-01-03. Estimated completion is 2022-06-23.
What interventions are being tested in trial NCT04221230?
The interventions under investigation include: Placebo (DRUG), NMRA-335140 (DRUG).
Who is sponsoring clinical trial NCT04221230?
This trial is sponsored by Neumora Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.